

## OriGene Technologies Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850 UNITED STATES

Phone: +1-858-888-7900 Fax: +1-858-888-7904 US-info@acris-antibodies.com

# OriGene EU

BP7192

#### **Acris Antibodies GmbH**

Schillerstr. 5 32052 Herford GERMANY

Phone: +49-5221-34606-0 Fax: +49-5221-34606-11 info@acris-antibodies.com

# Polyclonal Antibody to CDC42 / Rac-1 pSer71 - Aff - Purified

Catalog No.: BP7192
Quantity: 0.1 ml

Background: Rac, cdc42 and Rho A, B, and C are members of a small RhoGTPase family that bind and

hydrolyze GTP. GTP-bound Rac1 and cdc42 play a pivotal role in controlling cell shape, adhesion, growth and transformation. Active Rac1 is implicated in regulating serum response element (SRE), NFAT1 and nuclear factor KB (NF-KB) transcription activities. Activated Rac1 and cdc42 bind and activate PAK1, which in turn activates key downstream signaling proteins including MEKK-1 and JNK. Rac1 and cdc42 are phosphorylated on serine 71, a putative Akt site located between the protein-binding domain and GTP-binding domain. Phosphorylation of Rac1 on serine 71 regulates its GTP-binding and GTPase

activity.

Host: Rabbit

Immunogen: Chemically synthesized phosphopeptide derived from a region of human Rac1-protein that

contains serine 71

Remarks: The sequence is conserved in human and mouse Rac 1, 2, and 3, and cdc42 in

human, mouse, rat, dog and frog.

**Format: State:** Liquid Ig fraction

**Purification:** Epitope-specific affinity chromatography. The antibody has been negatively preadsorbed using a non-phosphopeptide corresponding to the site of phosphorylation to remove antibody that is reactive with non-phosphorylated Rac1. The final product is generated by affinity chromatography using a Rac1-derived peptide that is phosphorylated

at serine 71.

**Buffer System:** Dulbecco's phosphate buffered saline (without Mg2+ and Ca2+), pH 7.3 (+/- 0.1), 50% glycerol with 1.0 mg/mL BSA (lgG, protease free) as a carrier, containing

0.05 % sodium azide as preservative

**Applications:** Western blot (1:1000 starting dilution).

Positive Control Used: A431 cells treated with EGF.

Other applications not tested. Optimal dilutions are dependent on conditions and should

be determined by the user.

**Specificity:** This antibody is specific for Rac1/cdc42 [pS71].

Species: Human, Mouse, Rat, Dog, Frog.

Other species not tested.

Storage: Store the antibody at -20 °C. Can be shipped at 2 - 8 °C.

Avoid repeated freezing and thawing. Centrifuge vial before opening. Shelf life: One year from despatch.

For research and in vitro use only. Not for diagnostic or therapeutic work. Material Safety Datasheets are available at www.acris-antibodies.com or on request.

Acris Antibodies is now part of the OriGene family. Learn more at www.origene.com



OG/20121030



## BP7192: Polyclonal Antibody to CDC42 / Rac-1 pSer71 - Aff - Purified

#### **General Readings:**

Servitja, J.M., et al. (2003) Rac1 function is required for Src-induced transformation: Evidence of a role for Tiam1 and Vav2 in Rac activation by Src. J. Biol. Chem. 278(36):34339-34346.

Sundberg, L.J., et al. (2003) An endogenous inhibitor of focal adhesion kinase blocks Rac1/JNK- but not Ras/ERK-dependent signaling in vascular smooth muscle cells. J. Biol. Chem. 278(32):29783-29791.

Vidal, C., et al. (2002) Cdc42/Rac1-dependent activation of the p21-activated kinase (PAK) regulates human platelet lamellipodia spreading: implication of the cortical-actin binding protein cortactin. Blood 100(13):4462-4469.

Fukuda, T., et al. (2002) Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase. J. Biol. Chem. 277(21):19114-19121.

Kwon, T., et al. (2000) Akt protein kinase inhibits Rac1-GTP binding through phosphorylation at serine 71 of Rac1. J. Biol. Chem. 275(1):423-428.

Bishop, A.L., et al. (2000) Rho GTPases and their effector proteins. Biochem. J. 348(Pt 2):241-255.

Zhao, Z.S., et al. (1998) A conserved negative regulatory region in alphaPAK: inhibition of PAK kinases reveals their morphological roles downstream of Cdc42 and Rac1. Mol. Cell. Biol. 18(4):2153-2163.

Crespo, P., et al. (1997) Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the vav proto-oncogene product. Nature 385(6612):169-172.

#### Protocols:

#### **Western Blotting Procedure**

- 1. Lyse approximately 10e7 cells in 0.5 mL of ice cold Cell Lysis Buffer (formulation provided below). This buffer, a modified RIPA buffer, is suitable for recovery of most proteins, including membrane receptors, cytoskeletal-associated proteins, and soluble proteins. Other cell lysis buffer formulations, such as Laemmli sample buffer and Triton-X 100 buffer, are also compatible with this procedure. Additional optimization of the cell stimulation protocol and cell lysis procedure may be required for each specific application.
- 2. Remove the cellular debris by centrifuging the lysates at  $14,000 \times g$  for 10 minutes. Alternatively, lysates may be ultracentrifuged at  $100,000 \times g$  for 30 minutes for greater clarification.
- 3. Carefully decant the clarified cell lysates into clean tubes and determine the protein concentration using a suitable method, such as the Bradford assay. Polypropylene tubes are recommended for storing cell lysates.
- 4. React an aliquot of the lysate with an equal volume of 2x Laemmli Sample Buffer (125 mM Tris, pH 6.8, 10% glycerol, 10% SDS, 0.006% bromophenol blue, and 130 mM dithiothreitol [DTT]) and boil the mixture for 90 seconds at 100°C.
- 5. Load 10-30  $\mu g$  of the cell lysate into the wells of an appropriate single percentage or gradient minigel and resolve the proteins by SDS-PAGE.
- 6. In preparation for the Western transfer, cut a piece of PVDF membrane slightly larger than the gel. Soak the membrane in methanol for 1 minute, then rinse with ddH2O for 5 minutes. Alternatively, nitrocellulose may be used.
- 7. Soak the membrane, 2 pieces of Whatman paper, and Western apparatus sponges in transfer buffer (formulation provided below) for 2 minutes.
- 8. Assemble the gel and membrane into the sandwich apparatus.
- 9. Transfer the proteins at 140 mA for 60-90 minutes at room temperature.
- 10. Following the transfer, rinse the membrane with Tris buffered saline for 2 minutes.
- 11. Block the membrane with blocking buffer (formulation provided below) for one hour at room temperature or overnight at 4°C.
- 12. Incubate the blocked blot with primary antibody at a 1:1000 starting dilution in Tris buffered saline supplemented with 3% Ig-free BSA and 0.1% Tween 20 overnight at 4°C or for two hours at room temperature.





### BP7192: Polyclonal Antibody to CDC42 / Rac-1 pSer71 - Aff - Purified

13. Wash the blot with several changes of Tris buffered saline supplemented with 0.1% Tween 20.

14. Detect the antibody band using an appropriate secondary antibody, such as goat F(ab)2 anti-rabbit IgG alkaline phosphatase conjugate or goat F(ab)2 anti-rabbit IgG horseradish peroxidase conjugate in conjunction with your chemiluminescence reagents and instrumentation.

Cell Lysis Buffer Formulation: 10 mM Tris, pH 7.4 100 mM NaCl 1 mM EDTA 1 mM EGTA 1 mM NaF 20 mM Na4P2O7 2 mM Na3VO4 0.1% SDS 0.5% sodium deoxycholate 1% Triton-X 100 10% glycerol 1 mM PMSF (made from a 0.3 M stock in DMSO) or 1 mM AEBSF (water soluble version of PMSF) 60 μg/mL aprotinin 10 μg/mL leupeptin 1 µg/mL pepstatin (alternatively, protease inhibitor cocktail such as Sigma Cat. # P2714 may be used)

Transfer Buffer Formulation:
2.4 gm Tris base
14.2 gm glycine
200 mL methanol
Q.S. to 1 liter, then add 1 mL 10% SDS.
Cool to 4°C prior to use.

Tris Buffered Saline Formulation: 20 mM Tris-HCl, pH 7.4 0.9% NaCl

Blocking Buffer Formulation: 100 mL Tris buffered saline 5 gm BSA 0.1 mL Tween 20

#### **Peptide Competition Experiment**

The specificity of a Phosphorylation Site Specific Antibody (PSSA) in each experimental system can be confirmed through peptide competition. In this technique, aliquots of antibody are pre-incubated with peptide containing the sequence of the phosphopeptide immunogen used to raise the PSSA and the corresponding non-phosphopeptide. Following preincubation with the peptide, each antibody preparation is then used as a probe in antibody-based detection methods, such as Western blotting, immunocytochemistry, flow cytometry, or ELISA. With a PSSA specific for the phosphorylated target protein, pre-







incubation with an excess of peptide containing the sequence of the phosphopeptide immunogen will block all antigen binding sites, while pre-incubation with the corresponding non-phosphopeptide will not affect the antibody.

In performing the Peptide Competition Experiment, it is important to note that the optimal dilutions of both antibody and peptide should be determined empirically for each specific application. The optimal dilution of antibody in these procedures is below saturating, as determined by previous experiments in your system.

The optimal dilution of peptide used in these procedures will depend on the overall affinity or avidity of the antibody, as well as the quantity of the target antigen. A 50-150 fold molar excess of peptide to antibody is found to be effective for most peptide competition experiments.

In the example presented below, the PSSA is used as a dilution of 1:1000 and the peptides are used at a concentration of 333 nM. The total volume of the phosphopeptide and nonphosphopeptide pre-incubated antibody preparations is 2 mL, sufficient for probing Western blot strips, as well as for use in other antibody-based detection methods. Under these conditions, the molar excess of peptide to antibody is > / = 50.

#### Procedure:

- 1. Prepare three identical test samples, such as identical PVDF or nitrocellulose strips to which the protein of interest has been transferred. The test samples should be blocked using a blocking buffer, such as Tris buffered saline supplemented with 0.1% Tween 20, and either 5% BSA or 5% non-fat dried milk.
- 2. Prepare 6.5 mL of working antibody stock solution (1:1000 in this example) by adding 6.5  $\mu$ L of antibody stock solution to 6.5 mL of buffer containing blocking protein, such as TBS supplemented with 0.1% Tween 20, and either 3% BSA or 3% non-fat dried milk.
- 3. Apportion the unused PSSA into working aliquots and store at -20°C for future use (the stock PSSA contains 50% glycerol and will not freeze at this temperature).
- 4. Allow the lyophilized control peptides to reach room temperature, ideally under desiccation.
- 5. Reconstitute each of the control peptides to a concentration of 66.7  $\mu$ M with nanopure water. (i.e. for a peptide with a molecular mass of 1500, reconstitution with 1 mL water yields a solution with a concentration of 66.7  $\mu$ M).
- 6. Apportion the unused reconstituted peptide solutions into working aliquots and store at -20°C for future use.
- 7. Label 3 test tubes as follows:
- tube 1: water only no peptide control
- tube 2: phosphopeptide
- tube 3: non-phosphopeptide
- 8. Into each tube, pipette the following components
- tube 1: 2 mL diluted PSSA solution plus 10 μL nanopure water
- tube 2: 2 mL diluted PSSA solution plus 10 µL phosphopeptide
- tube 3: 2 mL diluted PSSA solution plus 10  $\mu$ L non-phosphopeptide
- 9. Incubate the three tubes for 30 minutes at room temperature with gentle rocking. During this incubation, the peptides have the chance to bind to the combining site of the antibody.
- 10. At the end of the incubation step, transfer the contents of each of the three tubes to clean reaction vessels containing one of the three identical test samples.

For Western blotting strips:

Incubate the strips with the pre-incubated antibody preparations for 1 hour at room temperature or overnight at 4°C.

Wash each strip four times, five minutes each, to remove unbound antibody. Transfer each strip to a new solution containing a labeled secondary antibody [e.g., goat F(ab)2 antirabbit IgG alkaline phosphatase conjugate or goat F(ab)2 anti-rabbit IgG horseradish





peroxidase conjugate.

Remove unbound secondary antibody by thorough washing, and develop the signal using your chemiluminescent reagents and instrumentation.

The signal obtained with antibody incubated with the "Water Only, No Peptide Control" (Tube 1), represents the maximum signal in the assay. This signal should be eliminated by preincubation with the "Phosphopeptide" (Tube 2), while pre-incubation with the "Non-Phosphopeptide" (Tube 3) should not impact the signal. If the "Phosphopeptide" only partially eliminates the signal, repeat the procedure using twice the volume of water or peptide solutions listed in Step 8. If partial competition is seen following pre-incubation with the "Non-Phosphopeptide", repeat the procedure using half the volumes of water or peptide solutions listed in Step 8.

**Pictures:** 

Up-regulation, Antibody-Peptide **Competition and Phosphatase Treatment** Extracts of A431 cells unstimulated (1) or stimulated with 200 ng/mL EGF for 15 minutes (2-6) were resolved by SDS-PAGE on a 10% Tris-glycine gel and transferred to PVDF. The membrane was either not treated (1-5) or treated with lambda (λ) phosphatase (6), blocked with a 5% BSA-TBST buffer for one hour at room temperature, then incubated with the Rac1/cdc42 [pS71] antibody for two hours at room temperature in a 3% BSA-TBST buffer, following prior incubation with: no peptide (1, 2, 6), the non-phosphopeptide corresponding to the phosphopeptide immunogen (3), a generic phosphoserine-containing peptide (4), or the phosphopeptide immunogen (5). After washing, the membrane was incubated with goat F(ab')2 anti-rabbit IgG HRP conjugate and signals were detected using the Pierce SuperSignalTM method. The data show that only the phosphopeptide corresponding to Rac1/cdc42 [pS71] blocks the antibody signal, demonstrating the site-specificity of the antibody. The data also show that phosphatase stripping eliminates the signal, further verifying that the antibody is phospho-specific.

